Diabetes treatment: The coming paradigm shift

Journal of Diabetes

Volumn 4, Issue 4, 2012, Pages 315-317

  Bloomgarden, Zachary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; CALCIUM ION; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADD ON THERAPY; CALCIUM CELL LEVEL; DIABETES MELLITUS; EDITORIAL; HUMAN; HYPOGLYCEMIA; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS;

EID: 84870317851     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12005     Document Type: Editorial

References (27)

1. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39.
2. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59.
3. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72.
4. Zimmet P, Bloomgarden ZT. How do we gauge the success of treatment of diabetes? J Diabetes. 2012; 4: 193-4.
5. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909.
6. Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410-8.
7. Seino S. Cell signalling in insulin secretion: The molecular targets of ATP, cAMP and sulfonylurea. Diabetologia. 2012; 55: 2096-108.
8. Gribble FM. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. Diabet Med. 2008; 25: 889-94.
9. Nauck MA, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007; 9: 194-205.
10. Göke B, Gallwitz B, Eriksson J et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract. 2010; 64: 1619-31.
11. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009; 11: 157-66.
12. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303: 1410-8.
13. Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: A primary care database analysis. Diabetes Obes Metab. 2012; Epub 3 August 2012. doi: 10.1111/j.1463-1326.2012.01674.x.
14. Nowicki M, Rychlik I, Haller H et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13: 523-32.
15. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes Obes Metab. 2012; Epub 20 April 2012. doi: 10.1111/j.1463-1326.2012.01610.x.
16. Engel SS, Williams-Herman DE, Golm GT et al. Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010; 64: 984-90.
17. Sehra D, Sehra S, Sehra ST. Sulfonylureas: Do we need to introspect safety again? Expert Opin Drug Saf. 2011; 10: 851-61.
18. Hung AM, Roumie CL, Greevy RA et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012; 81: 698-706.
19. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25: 2244-8.
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65.
21. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011; 27: 57-64.
22. Frederich R, Alexander JH, Fiedorek FT et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010; 122: 16-27.
23. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012; 11: 3.
24. Patil HR, Al Badarin FJ, Al Shami HA et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012; 110: 826-33.
25. Scirica BM, Bhatt DL, Braunwald E et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011; 162: 818-25.
26. White WB, Bakris GL, Bergenstal RM et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011; 162: 620-6.
27. Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig. 2012; 32: 189-202.